Can we try Opsumit (macitentan) for this patient with pulmonary arterial hypertension?

Can Opsumit (Macitentan) Be Used for This Patient?

Yes, Opsumit (macitentan) is an FDA-approved and guideline-recommended endothelin receptor antagonist for treating pulmonary arterial hypertension (PAH) in adults, with proven benefits in reducing disease progression, hospitalization, and mortality. 1

FDA-Approved Indication

Opsumit is specifically indicated for PAH (WHO Group I) to reduce the risks of disease progression and hospitalization. The approval was based on the landmark SERAPHIN trial involving patients with predominantly WHO Functional Class II-III symptoms, including those with idiopathic/heritable PAH (57%), connective tissue disease-associated PAH (31%), and congenital heart disease with repaired shunts (8%). 1

Evidence of Efficacy

Macitentan demonstrated a 45% reduction in the composite endpoint of morbidity and mortality in the pivotal SERAPHIN trial, with 742 PAH patients treated for an average of 100 weeks. 2, 3 The drug significantly reduced:

• Death, atrial septostomy, lung transplantation, or need for IV/subcutaneous prostanoids
• Disease progression events
• Exercise capacity improvements

The benefits were consistent whether patients were treatment-naïve or already receiving other PAH therapies. 2, 3

Treatment Strategy Based on Risk Assessment

According to ESC/ERS guidelines, your treatment decision should be guided by risk stratification 2:

Low-Risk Patients (WHO FC I-II with favorable parameters):

• Macitentan can be initiated as monotherapy or in combination with a PDE5 inhibitor
• Target: maintain low-risk status

Intermediate-Risk Patients:

• Upfront combination therapy with macitentan + PDE5 inhibitor is preferred 4, 5
• Recent data shows 39% mortality reduction with macitentan+PDE5i versus PDE5i alone 6

High-Risk Patients (WHO FC III-IV):

• Consider macitentan as add-on therapy to existing treatments 4
• For patients remaining symptomatic on established monotherapy, adding macitentan improves outcomes 4

Dosing and Administration

• Standard dose: 10 mg once daily 1
• No dose adjustment needed for hepatic or renal impairment
• Can be taken with or without food
• Higher doses (>10 mg) have not been studied and are not recommended 1

Critical Safety Considerations

Mandatory pregnancy exclusion: Macitentan carries a boxed warning for embryo-fetal toxicity. You must:

1. Exclude pregnancy before initiating treatment in females of reproductive potential 1
2. Ensure effective contraception during treatment and for 1 month after discontinuation
3. Discontinue immediately if pregnancy is detected 1

Hepatic monitoring: Unlike bosentan (which requires monthly liver function tests), macitentan showed no significant liver toxicity in clinical trials. However:

• Obtain baseline liver enzymes before starting 1
• Monitor during treatment as clinically indicated
• Discontinue if aminotransferases >3× ULN with bilirubin >2× ULN or clinical hepatotoxicity symptoms 1

Anemia monitoring: Hemoglobin reduction ≤8 g/dL occurred in 4.3% of patients on macitentan 10 mg. 2 Monitor hemoglobin at baseline and periodically during treatment.

Combination Therapy Considerations

When adding macitentan to existing therapy 4:

• For patients symptomatic on PDE5 inhibitor or inhaled prostanoid: macitentan improves 6-minute walk distance, WHO functional class, and delays clinical worsening
• For patients on bosentan, ambrisentan, or inhaled prostanoid: adding riociguat may be considered instead

Avoid combining with other ERAs (bosentan, ambrisentan) as this provides no additional benefit and increases toxicity risk.

Real-World Evidence

The combined OPUS/OrPHeUS registries (5,654 patients, 81.9% with PAH) demonstrated 7:

• Median exposure: 14.5 months
• Discontinuation due to adverse events: 17.1% (non-hepatic), 0.3% (hepatic)
• 90.4% survival at 1 year
• Well-tolerated across diverse PAH populations

Common Pitfalls to Avoid

1. Do not use in pregnancy - This is an absolute contraindication 1
2. Do not combine with other ERAs - No added benefit, increased toxicity
3. Do not skip risk stratification - Treatment intensity should match disease severity 2
4. Do not delay escalation - If patient remains intermediate/high-risk on macitentan monotherapy after 3-6 months, add second agent 2, 4

Follow-Up Protocol

After initiating macitentan, reassess every 3-6 months with 2:

• WHO functional class
• 6-minute walk test
• NT-proBNP or BNP levels
• Echocardiography
• Consider repeat right heart catheterization if clinical status unclear

Target: Achievement and maintenance of low-risk profile is the treatment goal. 2